Qualification
MBBS, MD, DM (Endocrinology)Languages
English Hindi Kannada Tamil TeluguWork Experience
23 Years Experience Overall (8 years as specialist)Research Experience
• A phase II 12-week randomizeddouble-blind
parallel group
placebo-controlled study to evaluate the safety
tolerability
and efficacy of GRC 8200 a new oral DPP IV inhibitor
in patients with Type 2 Diabetes mellitus
• A randomized
double-blind
active-controlled
multicentre study to compare the effect of 24 weeks of treatment with a fixed-dose combination therapy of Vildagliptin / Metformin to individual mono-therapies in drug naïve patients with Type 2 Diabetes mellitus.
• A randomized
double-blind
placebo-controlled
parallel-group efficacy and safety study of BI 1356 (5mg administered orally once daily) over 24 weeks in type 2 diabetic patients with insufficient glycemic control despite metformin therapy.
• A longitudinal nationwide study on management and real-world outcomes of Diabetes in India. (Principal Investigator)
• Co-investigator in Clinical Trials – ICON study
ORIGN –study
Glargine Vs Premix analogues
Levemir Vs Glargine
Awards & Achivements
• Best Award Paper in KAPICON 2008 NARENDRA BS. Block and Replacement for Graves’s Disease: How good are we now?• Best Poster in KAPICON 2008 NARENDRA BS
Sehgal M
Menaka R
Bhattacharyya A. Patient satisfaction for different therapies for Graves’ disease
Memberships
• Karnataka Medical Council (KMC)• ADA
• AACE
• Endocrine Society of India (ESI)
• Indian Thyroid Society (ITS)
• ISBMR
• Karnataka Endocrine Society (KES)
Area of Interest
• Comprehensive management of Type 1 & Type 2 Diabetes mellitus• Gestational Diabetes mellitus (Pregnancy Diabetes)
• Continuous Glucose management (CGM)
• Insulin Pump management
• Thyroid disorders – Hypothyroid
Hyperthyroid
Thyroid nodules
Thyr